-
Site for INHALE-1: A 26-week Primary Treatment Phase with 26-week Extension Open-label Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza Versus Rapid-acting Insulin Analog Injections Both in Combination with a Basal Insulin in Pediatric Subjects with Type 1 or Type 2 Diabetes Mellitus
Site for MKC-TI-155 Part 2 is a Phase 3, open-label, randomized clinical study evaluating the efficacy and safety of Afrezza in combination with a basal ... -
Melanoma Margins Trial (MelMarT): A Phase III Multi-Centre Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
This study will determine whether there is a difference in disease free survival for patients treated with either a 1cm excision margin or 2cm margin ... -
Feasibility of Using Wearable Sensors and Artificial Intelligence for Carbohydrate Counting in Chinese Americans with Type 2 Diabetes
Chinese Americans are one of the fastest growing racial/ethnic groups in the United States. Compared with non-Hispanic White, Chinese Americans have a higher incidence ... -
A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED MULTICENTER OUTPATIENT PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM IN PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH EPILEPSY WITH A PREDICTABLE SEIZURE PATTERN.
Staccato alprazolam is being developed for the indication of rapid cessation of a prolonged focal or generalized seizure that has not progressed to status epilepticus ... -
EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence
EMBER-4 is a Phase 3 global, randomized, open-label study of adjuvant imlunestrant vs SOC adjuvant ET of physician’s choice in participants who have previously ... -
Integrating financial coaching and smoking cessation coaching for people with low income who smoke: a randomized controlled trial
This study conduct a two-arm, parallel-group randomized controlled trial. We will recruit and randomize 900 smokers (n=450 per arm) to either: (1) Control: Standard ... -
ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease chronic kidney disease and systemic inflammation
ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation -
Randomized multicenter open-label phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRa-positive recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second line platinum-based chemotherapy plus bevacizumab(GOG 3078)
The purposes of this study are: • To determine if mirvetuximab soravtansine (MIRV) plus BEV is effective at managing subjects' type of cancer in a maintenance ... -
The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis
This is a randomised, multicentre, double-blinded, parallel-group trial comparing semaglutide s.c. 2.4 mg once-weekly versus placebo in subjects with NASH and fibrosis stage ... -
PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE WITH A NON RANDOMIZED SINGLE ARM US EXTENSION OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER AT LEAST ONE LINE OF SYSTEMIC THERAPY
This is a Phase III, open-label, multicenter, randomized controlled trial in patients with R/R FL after receiving at least 1 line of systemic therapy ...